Ownership Summary
Addex Therapeutics Ltd. (NASDAQ:ADXN) currently has 3 active institutional owners and shareholders as of today (December 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).
- These investors collectively held 0.0% of the company's total shares outstanding in December 2025, up from 0.0% in September 2025.
- Quarterly data indicates a 87.40% shift in institutional share volume, and the annual owner count reflects a decrease of 50.00%.
- Among the 3 institutional holders of Addex Therapeutics, 1 added to their stakes while 2 trimmed their positions and 0 held steady.
- The aggregate institutional position in Addex Therapeutics now stands at 238 shares as of December 2025, after investors increased their holdings (up by 111 shares quarter on quarter which is down 14.86K shares year over year).
- UBS Group AG's holding of 156 shares as of December 31, 2025 makes it the primary institutional investor in Addex Therapeutics, owning 0.00% of the stock.
- Among the most significant buyers of Addex Therapeutics during December 2025 were UBS Group AG (155).
- Leading sellers of Addex Therapeutics stock in December 2025 included GAMMA Investing LLC (40), SBI Securities Co., Ltd. (4).
- The top 3 institutional holders of Addex Therapeutics for the quarter ending December 2025 included UBS Group AG (156), GAMMA Investing LLC (81), SBI Securities Co., Ltd. (1).